The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo-controlled study

American Journal of Hypertension

Volumn 13, Issue 5 II SUPPL., 2000, Pages 468-474

  Black, Henry R ^a   Sollins, Jeffrey S ^b   Garofalo, James L ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antihypertensive; Blood pressure; Doxazosin; Hypertension; Lipids

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; SAFETY;

EID: 0034126205     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00225-3     Document Type: Article

References (21)

1. Joint National Committee: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446.
2. Materson BJ, Reda DJ, Cushman WC: Department of veterans affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189-192.
3. Messerli F: Combination therapy in hypertension. J Hum Hypertens 1992;6(suppl 2):S19-S21.
4. MacConnachie A, Maclean D: Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Saf 1995;12:85-90.
5. Grimm RH Jr, Flack J, Schoenberger J, Gonzalez NM, Liebson PR: Alpha-blockade and thiazide treatment of hypertension: a double-blind randomized trial comparing doxazosin and hydrochlorothiazide. Am J Hypertens 1996;9:445-454.
6. Neaton J, Grimm R Jr, Prineas R, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R: Treatment of Mild Hypertension Study. JAMA 1993;270:713-724.
7. Shionoiri H, Ashino K, Yamanaka K, Shindo K, Hiroto S, Arita T: Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin Ther 1997;19: 527-536.
8. Englert RG, Barlage U: The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. Am Heart J 1991;121:311-316.
9. Lindner UK, von Manteuffel GE, Stafunsky M: The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988;116:1814-1820.
10. Searle M, Dathan R, Dean S, Christensen CC, Westheim A: Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 1990;39:299-300.
11. Englert RG, Mauersberger H: A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988;116: 1826-1832.
12. Brown MJ, Dickerson JE: Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1991; 9(suppl):S362-S363.
13. Donnelly R, Elliott HL, Meredith PA, Howie CA, Reid JL: Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992;19:479-486.
14. Troffa C, Manunta P, Dessi-Fulgheri P: Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res 1994;55:22-31.
15. Brown M, Dickerson J: Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens 1995;13:701-707.
16. Fulton B, Wagstaff A, Sorkin E: Doxazosin: An update of its clinical pharmacology and therapeutic applications in the treatment of hypertension and BPH. Drugs 1995;49:295-320.
17. Talseth T, Westlie L, Daae L: Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. Am Heart J 1991;121:280-285.
18. Grimm R Jr, Flack J, Grandits G, Elmer PJ, Newton JD, Cutler JA, Lewis C, McDonald R, Schoenberger J, Stamler J: Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996;275:1549-1556.
19. Pickering T, Levenstein M, Walmsley P: Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Am J Hypertens 1994;7: 844-847.
20. Levy D, Walmsley P, Levenstein M: Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996;131:966-973.
21. Gillenwater J, Conn R, Chrysant S, Roy J, Gaffney M, Ice K, Dias N: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154:110-115.